These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 18212313)

  • 1. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
    D'Amico AV; Chen MH; Renshaw AA; Loffredo M; Kantoff PW
    JAMA; 2008 Jan; 299(3):289-95. PubMed ID: 18212313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group.
    Nguyen PL; Chen MH; Beard CJ; Suh WW; Renshaw AA; Loffredo M; McMahon E; Kantoff PW; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1046-52. PubMed ID: 19864082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction.
    Nanda A; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
    JAMA; 2009 Aug; 302(8):866-73. PubMed ID: 19706860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
    D'Amico AV; Manola J; Loffredo M; Renshaw AA; DellaCroce A; Kantoff PW
    JAMA; 2004 Aug; 292(7):821-7. PubMed ID: 15315996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence.
    Wo JY; Chen MH; Nguyen PL; Renshaw AA; Loffredo MJ; Kantoff PW; D'Amico AV
    J Clin Oncol; 2009 Dec; 27(35):6000-5. PubMed ID: 19858385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death.
    D'Amico AV; Chen MH; Renshaw AA; Loffredo M; Kantoff PW
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):10-5. PubMed ID: 19395184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial.
    Royce TJ; Chen MH; Wu J; Loffredo M; Renshaw AA; Kantoff PW; D'Amico AV
    JAMA Oncol; 2017 May; 3(5):652-658. PubMed ID: 28097317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level.
    D'Amico AV; Loffredo M; Renshaw AA; Loffredo B; Chen MH
    J Clin Oncol; 2006 Sep; 24(25):4190-5. PubMed ID: 16943536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of the anti-androgen in men undergoing 6 months of an LHRH agonist and radiation therapy for unfavorable-risk prostate cancer and the risk of death.
    Sanford NN; Chen MH; Loffredo M; Renshaw A; Kantoff PW; D'Amico AV
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):79-84. PubMed ID: 27824043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer.
    D'Amico AV; Schultz D; Loffredo M; Dugal R; Hurwitz M; Kaplan I; Beard CJ; Renshaw AA; Kantoff PW
    JAMA; 2000 Sep; 284(10):1280-3. PubMed ID: 10979115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
    Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
    Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of Local Control in Early-Stage Prostate Cancer: Outcomes of Patients With Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408.
    Krauss DJ; Hu C; Bahary JP; Souhami L; Gore EM; Chafe SM; Leibenhaut MH; Narayan S; Torres-Roca J; Michalski J; Zeitzer KL; Donavanik V; Sandler H; McGowan DG; Jones CU; Shipley WU
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):863-73. PubMed ID: 26104939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
    Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
    BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
    Pilepich MV; Winter K; John MJ; Mesic JB; Sause W; Rubin P; Lawton C; Machtay M; Grignon D
    Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1243-52. PubMed ID: 11483335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer.
    D'Amico AV; Chen MH; Renshaw AA; Loffredo M; Kantoff PW
    Cancer; 2008 Dec; 113(12):3290-7. PubMed ID: 18980297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902.
    Rosenthal SA; Hunt D; Sartor AO; Pienta KJ; Gomella L; Grignon D; Rajan R; Kerlin KJ; Jones CU; Dobelbower M; Shipley WU; Zeitzer K; Hamstra DA; Donavanik V; Rotman M; Hartford AC; Michalski J; Seider M; Kim H; Kuban DA; Moughan J; Sandler H
    Int J Radiat Oncol Biol Phys; 2015 Oct; 93(2):294-302. PubMed ID: 26209502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
    Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy.
    D'Amico AV; Chen MH; Renshaw AA; Loffredo B; Kantoff PW
    J Clin Oncol; 2008 Jun; 26(18):2979-83. PubMed ID: 18565884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer.
    Efstathiou JA; Chen MH; Renshaw AA; Loffredo MJ; D'Amico AV
    Cancer; 2007 Apr; 109(8):1493-8. PubMed ID: 17340594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.
    Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1439-44. PubMed ID: 19540066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.